Why Regado May be Oversold

By DrKSSMDPhD, July 27, 2014

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading rules and he chooses his own topics. His words and opinions are his own. Enjoy!]

In June 1962, women working in the dressmaking arm of a certain American textile factory were overcome with fear. Rumors began to fly that a mysterious insect had infested the factory, that it could get into your hair, and that if it bit you, you’d get dizziness, nausea, and tingling limbs. Though company doctors could find absolutely no evidence of a bug in either the literal or metaphoric sense, a total of 62 women claimed to be sickened by “the June bug,” and some insisted on being hospitalized. Nothing ailed them except hysteria.

Tanzanian schoolchildren suffered from an outbreak of contagious laughter, also in 1962. It went on for nearly a year, and led to the closing down of 14 schools in the region near the border with Kenya, as children would show up only to giggle non-stop, in a belief that some mysterious force was driving the laughter.

You may also have heard about the Pokemon Epilepsy Outbreak. Or the 2009 Fort Worth Perfume Panic, in which dozens were “sickened” by what they thought was carbon monoxide in the air (it was perfume from a factory…and of course, carbon monoxide has no odor). Or the 2006 Portuguese mystery virus epidemic that “sickened” hundreds of children in the wake of it being depicted on a teen soap opera called Strawberries with Sugar. Memes are just as contagious, and just as compelling epidemiologically, as Ebola virus.

Right now, Regado investors, most of them, are sickened by the July Malaise.

In April 2014, I introduced Regado Biosciences (RGDO) as a cause for solace and optimism in the context of the biotech market behaving brutally. In the thread following that column, there was unusual acrimony, with certain addled readers accusing me of having ulterior motives in presenting RGDO. How presenting a novel company with a unique methodology for a serious clinical issue, so that potential investors could do their own due diligence on it—how that could be malfeasance on my part was never specified. At least two discussion threads on Gumshoe, some of them with ripe quarter-deck language, have been started for the purpose of bashing me for presenting Regado. As with any stock ...

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

Sign Up for a Premium Membership

To view the rest of this article (and to have full access to the rest of our articles), sign up.
Already a member, log in.

Become a member